Meta AnalysisID 6125
口服中成药联合常规西药治疗寻常型银屑病的有效性与安全性：系统评价与贝叶斯网状Meta分析方案
CRD42021227204
What is the efficacy and safety of oral Chinese patent medicine for patients with psoriasis vulgaris?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6125
- Evidence Id
- 14683
- Core Evidence Id
- 14683
- Source Meta Analysis Id
- 6105
- Herb2 Meta Analysis Id
- HBMA006105
- Crd Id
- CRD42021227204
- Title
- Effectiveness and safety of Oral Chinese Patent Medicine combined with Conventional Western Medicine in the treatment of psoriasis vulgaris：A protocol for systematic review and Bayesian network meta-analysis
- Review Question
- What is the efficacy and safety of oral Chinese patent medicine for patients with psoriasis vulgaris?
- Study Type Included
- Randomized controlled trials
- Condition Being Studied
- Psoriasis is a chronic inflammatory skin disease that affects 2–3% of the global population。Psoriasis vulgaris is the most common disease type，affects 80% to 90% of psoriasis patients。This disease results in a serious burden on affected patients as well as their families。
- Participant
- Patients diagnosed with PSV according to any of the diagnostic criteria are eligible to be included, such as standard refers to the diagnostic criteria for psoriasis in “Dermatovenerology,” “China Clinical Dermatology,” or “Integrated Chinese and Western Medicine Skin Dermatology.” The patient must be at least 18 years old. Gender、nationality and race are not restricted.
- Animal
- Human Disease Modelled
- Intervention
- The treatment group is defined as treating with the combination of oral Chinese patent medicine（OCPMs）and Conventional Western Medicine treatments. Conventional Western Medicine treatments include topical agents, systemic agents, and phototherapy. The control group is defined as treating with the Conventional Western medicine treatments only. The basic treatments of both groups are consistent. According to the clinical guidelines and expert consensus on application of OCPMs in the treatment of psoriasis, OCPMs mainly include Compound Qingdai Capsule, Compound Qingdai Pill, Xiaoyin Granule, Xiaoyin Capsule, Xiaoyin Tablets, Babaowudanyaomo, Keyin Pill, Zidan Yinxie Capsule, Yujin Yinxie Tablets, Yinxie Capsule, Kuda Pill, Yinxielin Granule, LiaoXuanKaXiFu Pill, and Runzao Zhiyang Capsule.
- Comparator Control
- The control group is defined as treating with the Conventional Western medicine treatments only. The basic treatments of both groups are consistent.
- Main Outcome
- The primary efficacy outcomes include PASI 60 and PASI 90. Psoriasis Area and Severity Index 60（PASI 60），i.e., (pretreatment PASI score - post-treatment PASI score) / pretreatment PASI score ×100% ≥ 60%. PASI 90，i.e., (pretreatment PASI score - post-treatment PASI score) / pretreatment PASI score ×100% ≥90%. Measures of effect Changes in disease severity, as evaluated using the Psoriasis Area and Severity Index (PASI): the proportion of patients achieving PASI 60, i.e., a 60% or greater reduction in PASI scores compared with the baseline.
- Outcome Measure
- Additional Outcome
- The second outcome measure is the adverse reactions. Measures of effect As above.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- China; Humans; Medicine, Chinese Traditional; Meta-Analysis as Topic; Network Meta-Analysis; Nonprescription Drugs; Psoriasis
- Contact
- Winghung Lai [email protected]
- Organisational Affiliation
- 1. Guangdong Provincial Hospital of Chinese Medicine, Guangzhou; 2. Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou; 3. The Second Clinical School of Guangzhou University of Chinese Medicine; 4.State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
- Funding Source
- 1.Guangdong Science and Technology project; 2. State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> 2017A020213011; SZ2020ZZ15
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-12-19
- Registration Date
- 2021-01-19
- Anticipated Start Date
- 2020-12-20
- Anticipated Completion Date
- 2022-08-12
- Title Cn
- 口服中成药联合常规西药治疗寻常型银屑病的有效性与安全性：系统评价与贝叶斯网状Meta分析方案
- Title En
- Effectiveness and safety of Oral Chinese Patent Medicine combined with Conventional Western Medicine in the treatment of psoriasis vulgaris：A protocol for systematic review and Bayesian network meta-analysis
- Bilingual Status
- complete